Business
Update on progress of Phase I/IIa Clinical Trial
Update on progress of Phase I/IIa Clinical Trial.
About this update from Immupharma Plc
[{"type":"text","content":"\n \n\n\n\n\n\nRNS Number : 5378B Immupharma PLC 21 February 2011 \n \n\n\n\n\n\nFor Immediate Release\n\n\n21 February 2011\n\n\n\n\n \nImmuPharma plc\n \nUpdate on progress of Phase I/IIa Clinical Trial with IPP-204106: Cancer patients stabilised with ImmuPharma's Cancer Compound\n\n \nImmuPharma plc (LSE:IMM) (\"Immupharma\" or the \"Company\" or the \"Group\"), the specialist discovery and development pharmaceutical company is pleased to announce encouraging results from its ongoing phase I/IIa clinical trial in cancer patients:\n \nKey Highlights:\n \n· Around half of the cancer patients that have undergone treatment with ImmuPharma's drug candidate IPP-204106 are in stable condition (their disease has stopped progressing) without any other drug treatment. All the patients that enrolled in the study were suffering from advanced cancer with metastases and had all failed their previous treatments with other existing cancer drugs.\n\n· The third dose level of IPP-204106 has just begun in the next group of patients. ImmuPharma's clinical trial began last summer and up to now two lower dose levels have been tested. The initial dose level of 1 mg/kg did not show any drug-related side effects. The first patient to be treated in this study is still alive and with stable disease 8 months after starting treatment with ImmuPharma's cancer compound. The second dose level of 2 mg/kg also did not show any drug-related side effects.\n\n· ImmuPharma has already begun development of the next generation of IPP-204106, the \"micro Nucants\". This improved formulation comprising of small particles of the drug candidate has shown an even more impressive efficacy in cancer models.\n \nThe clinical trial is taking place in two hospitals in Paris and one hospital in Dijon, in France and is expected to complete in the coming months. Further details and analysis will be provided at the end of the study.\n \nImmuPharma hopes to start a Phase IIb programme later this year in patients with glioblastoma (brain tumour), hormone-resistant prostate cancer and pancreatic cancer.\n \nDr Robert Zimmer, MD, PhD, ImmuPharma's President and Chief Scientific Officer commented: \"It is indeed a pleasure and...